BioSpace News Archive

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, reported financial results for the third quarter ended September 30, 2021.

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three posters with preclinical data of its innate cell engagers (ICE®) are presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

Editas Medicine, Inc., a leading genome editing company, announced preclinical data on its progress in the development of novel engineered induced pluripotent stem cell -derived natural killer cells for the treatment of cancer.

Agenus, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the presentation of new clinical data for AGEN1181 as monotherapy and in combination with balstilimab at the Society for Immunotherapy of Cancer 36th Annual Meeting.

Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the 2021 Jefferies London Healthcare Conference.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced the presentation of new preclinical data on NL-201, an alpha-independent, de novo-designed IL-2 and IL-15 dual agonist, at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021).

Talaris Therapeutics, Inc. (Nasdaq: TALS), today reported financial results for the three- and nine-month periods ended September 30, 2021, and provided an update on its business.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer in Washington, D.C.

Oncorus, Inc. (Nasdaq: ONCR), today presented initial safety, tolerability and immune activation and clinical response data from its ongoing Phase 1 open-label, multi-center, dose escalation and expansion clinical trial of ONCR-177 at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.